|Bid||4.6500 x 800|
|Ask||4.6700 x 2200|
|Day's Range||4.5800 - 4.7900|
|52 Week Range||0.2700 - 34.0000|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||0.11|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.